InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,475.09
(
0.27%
)
US TECH 100
19,250.80
(
0.45%
)
Dow Jones
39,169.52
(
0.13%
)
Brent Oil
86.67
(
0.16%
)
Bitcoin
62,932.04
(
0.13%
)
Post# of 13742
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JediMozart

Send PM Follow Ignore
Followers 8
Posts 628
Boards Moderated 0
Alias Born 05/26/2021

JediMozart

Member Level

Re: None

Monday, 11/29/2021 7:54:38 AM

Monday, November 29, 2021 7:54:38 AM

Post# of 13742
Pre-IND / NDA STRATEGY
Escozine®/ Covid-19: Data on Escozine® has been filed under pre-IND with US FDA as a potential COVID1-19. Clinical studies showing efficacy and safety of product

Escozine® GNP-1/ Pancreatic Cancer (Orphan Drug):
As a critical medicine for the Covid-19 Pandemic, we anticipate the approval of the product, in a shorter time period. Given that Scorpion Peptide is the main ingredient for Escozine/ Covid-19 and Escozine GNP-1, we strategize that the approval of the Escozine/Covid-19 drug can facilitate the fast tracking to the second phase of Escozine GNP-1/Pancreatic Cancer drug study.

https://medoliferx.com/clinical-strategy/

Cyber Monday shopping :)
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up